Jake Van Naarden, who rules the oncology roost at Eli Lilly, is back in the dealmaking game. Monday morning he uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million — $300…
Though IPO activity has slowed in the US significantly, a Qiming Venture-backed biotech took the public leap in a Hong Kong debut Friday. CANbridge Pharmaceuticals began trading on the HKEX after…
When Bristol Myers Squibb celebrated the approval of ozanimod — branded Zeposia — in ulcerative colitis earlier this year, the company touted the first gastrointestinal indication for an S1P receptor…
The Ocular Drug Delivery Technology Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this Ocular Drug Delivery Technology Market report is to
Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced a collaboration to…
Overall, approximately 41% of those receiving Axi-cel and 16% of those receiving standard of care survived for 2 years without needing additional cancer treatment or experiencing cancer progression.
This report on the global Gene Editing Technology Market Size & Forecasting Market gives a thorough study that is primarily focused on top players and their business stratagem, geographical extent, market segments, competitive landscape, manufacturing, and pricing and cost structures.
Responses to Johnson & Johnson’s BCMA CAR-T therapy are going on and on and on. After a median follow-up of 22 months, a phase 1b/2 clinical trial of the Legend Biotech-partnered cell therapy is yet…
Study results mean the bispecific antibody treatment is likely to secure FDA approval and rival a custom-made CAR-T therapy.
New data on CAR-T therapy, called cilta-cel, suggests the treatment might help halt progression of multiple myeloma for nearly two years.
